R.P 2.1 Clinical Translation of a Novel Anti-Microbial Therapy for Eye Infections

Overview

Methicillin-resistant Staphylococcus aureus (MRSA), a major antimicrobial-resistant pathogen, poses a serious global health threat, especially in ocular and skin infections. This project aims to translate and commercialize a novel drug-based antimicrobial therapy to treat eye infections, addressing the growing challenge of resistance to existing antibiotics. Building on prior discoveries of a highly effective combination therapy that markedly enhances antimicrobial activity against drug-resistant pathogens, the study focuses on advancing this treatment toward clinical use. Key work includes comprehensive preclinical evaluations of efficacy, safety, pharmacokinetics, and drug metabolism, alongside optimization of next-generation antimicrobial combinations through rational drug design and repurposing of approved compounds.